This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Comorbid Depressive and Anxiety Disorders

Nisha Ravindran, MDa,b; Martha McKay, PhDc; Angela Paric, PhDa,b; Sunny Johnson, MDd; Ranjith Chandrasena, MDe; Gaby Abraham, MDa; and Arun V. Ravindran, MD, PhDa,b,*

Published: March 21, 2022

ABSTRACT

Objective: Quetiapine is approved as an adjunctive treatment for major depressive disorder (MDD) and as monotherapy for bipolar depression. It is often used off-label for treating anxiety conditions and as an augmentation agent for treatment-resistant depression. However, its benefit in depression with comorbid anxiety disorders has not been systematically evaluated. The current study evaluated the benefit and tolerability of quetiapine as augmentation to first-line antidepressants for MDD comorbid with anxiety disorders.

Methods: In this multicenter trial (June 2008–June 2013), 76 adults (aged 18–65 years) with a primary diagnosis of unipolar depression comorbid with at least 1 anxiety disorder (per DSM-IV-TR criteria) received flexible-dose quetiapine extended-release (XR) 50–300 mg/d or placebo as add-on for 12 weeks in a 2:1 ratio. Depression, anxiety, life satisfaction, and adverse events were assessed.

Results: Depression, anxiety, and function improved significantly in both groups. On primary outcome measures, quetiapine was superior to placebo in improving depression (17-item Hamilton Depression Rating Scale score: mean difference = −3.64; 95% CI, −7.01 to –0.27) and anxiety symptoms (Hamilton Anxiety Rating Scale score: mean difference = –4.02; 95% CI, −7.41 to –0.64), as well as Clinical Global Impressions–Severity of Illness scale score (mean difference = –0.64; 95% CI, −1.13 to –0.15). On secondary measures including the Montgomery-Asberg Depression Rating Scale, Beck Depression Inventory, Penn State Worry Questionnaire, and Quality of Life Satisfaction and Enjoyment Questionnaire, quetiapine produced a greater degree of improvement compared to placebo, but group differences were not statistically significant. Quetiapine was well tolerated, with mostly minor and no serious adverse effects.

Conclusions: Quetiapine augmentation may be a useful intervention for MDD with comorbid anxiety.

Trial Registration: ClinicalTrials.gov Identifier: NCT00688818

Volume: 83

Quick Links: Anxiety , Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Telehealth of Coordinated Specialty Care in Early Psychosis During COVID-19

As the COVID-19 pandemic emerged in 2020, access to in-person clinical care was restricted. This study explored...

Read More...